Description

Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1].–Applications-Cancer-programmed cell death-Formula-C37H64N6O8S-Citation–References-[1]Kevin HAMBLETT, et al. Anti-her2 biparatopic antibody-drug conjugates and methods of use. Patent WO2019173911A1.-CASNumber-1800462-99-0-MolecularWeight-753.00-Compound Purity–SMILES-C[C@@H](C(N[S](=O)(C(C=C1)=CC=C1N)=O)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@@H](N(C)C)C(C)C)=O)=O)=O)OC-Research_Area-Cancer-Solubility-DMSO : 330 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC;Microtubule/Tubulin-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related